BFC
EVFM

Bedel Financial Consulting’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Bedel Financial Consulting’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500
Closed -$17K – 1112
2021
Q3 		$17K Buy
+1,500
New +$18.8K 0.01% 583

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bedel Financial Consulting's EVFM Position: Q4 2021 in Review

Bedel Financial Consulting sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 1,500 shares — an estimated $17K sold.

Bedel Financial Consulting first reported a position in EVFM in Q3 2021 and held it in 1 quarter. The position peaked at $17K in Q3 2021. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

  • Bedel Financial Consulting reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Bedel Financial Consulting sold 1,500 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $17K.
  • Bedel Financial Consulting first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Bedel Financial Consulting's Evofem Biosciences, Inc. Common Stock position peaked at $17K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Bedel Financial Consulting's 13F filing for Q4 2021, filed 11 Jan 2022.